D
Design Therapeutics
Developing a new class of therapies for serious degenerative disorders
About Design Therapeutics
DesignTx is a biopharmaceutical company focused on developing novel small molecule therapeutic candidates aimed at providing functional cures for serious genetic diseases with long-standing unmet needs. Operating within the biopharmaceutical sector, DesignTx leverages its Gene Targeted Chimera platform to harness the power of small molecules and deep understanding of gene regulation. The company's target clients include patients suffering from debilitating genetic disorders, healthcare providers, and research institutions. DesignTx's business model revolves around the research, development, and commercialization of its therapeutic candidates. Revenue is generated through the sale of these therapies, partnerships, and potential licensing agreements. The company is driven by a team of global leaders in DNA-targeted small molecules, transcription modulation, and medicinal chemistry, ensuring a robust pipeline of innovative treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Carlsbad, United States
- Employees
- 67
- Open positions
- None listed
- Dealroom signal
- 77.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Mar 2021 | $276M | $276M | Undisclosed | — |
| SERIES BOther financing | Jan 2021 | $125M | $500M | Wellington Management · BlackRock · SR One · Citadel | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Design Therapeutics is 4.5K monthly website visits, up 28.6% over the last three months. Design Therapeutics's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Design Therapeutics in the Carlsbad ecosystem
The Design Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series A13 investors entered at this stage
SR One
Cormorant Asset Management
Quan Capital
WestRiver Group
Logos Capital
Wellington Management
BlackRock
CitadelJanus Henderson Investors
T. Rowe Price
Avoro Capital Advisors
Vivo Capital
RA Capital Management
Other known investors1 additional known investor
University of Wisconsin-Madison
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Design Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Design Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









